|
Market Closed -
Nasdaq
00:00:00 18/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.8500 USD | +4.94% |
|
+6.22% | +22.71% |
| 08-18 | Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. | CI |
| 08-14 | Elutia Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
| Market Cap | 37.65M 32.79M 31.03M 28.2M 52.67M 3.61B 52.93M 370M 143M 1.83B 141M 138M 5.87B | P/E 2026 * |
-1.35x | P/E 2027 * | -1.57x |
|---|---|---|---|---|---|
| Enterprise Value | 37.65M 32.79M 31.03M 28.2M 52.67M 3.61B 52.93M 370M 143M 1.83B 141M 138M 5.87B | EV / Sales 2026 * |
5.02x | EV / Sales 2027 * | 8.75x |
| Free-Float |
85.26% | Yield 2026 * |
-
| Yield 2027 * | - |
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ELUT | Delayed | |
CBOE
| ELUT | Real-time |
Last Transcript: Elutia Inc.
| 1 day | +4.94% | ||
| 1 week | +6.22% | ||
| Current month | -1.63% | ||
| 1 month | -12.90% | ||
| 3 months | -14.26% | ||
| 6 months | -22.02% | ||
| Current year | +22.71% |
| 1 week | 0.77 |  | 0.89 |
| 1 month | 0.77 | | 1.05 |
| Current year | 0.6 | | 1.38 |
| 1 year | 0.5 | | 1.38 |
| 3 years | 0.5 | | 5.24 |
| 5 years | 0.5 | | 9.01 |
| 10 years | 0.5 | | 18.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Operating Officer | 52 | - | |
Charles Mills
CEO | Chief Executive Officer | 54 | 21/06/2022 |
Matthew Ferguson
DFI | Director of Finance/CFO | 58 | 28/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Rakin
CHM | Chairman | 65 | 01/11/2015 |
Charles Mills
BRD | Director/Board Member | 54 | 01/11/2015 |
Brigid Makes
BRD | Director/Board Member | 70 | 01/09/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/09/26 | Exercice | Founder | 63,884 | 0.1445% | ||
| 10/09/26 | Exercice | Founder | 29,269 | 0.0662% | ||
| 10/09/26 | Exercice | Chief Financial Officer | 29,486 | 0.0667% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.94% | +6.22% | -24.78% | -24.78% | 35.87M | |
| +1.92% | -0.48% | +34.83% | -4.12% | 77.35B | |
| -0.35% | +5.90% | -10.78% | -33.39% | 59.58B | |
| +8.55% | +15.70% | +532.28% | +37.94% | 58.14B | |
| -0.92% | -1.90% | -10.99% | +24.21% | 47.62B | |
| +1.21% | +3.42% | +2.76% | +147.74% | 45.34B | |
| +1.41% | +1.68% | +51.20% | -14.03% | 31.92B | |
| +2.30% | +3.52% | +50.50% | +104.03% | 25.29B | |
| +2.18% | +1.91% | -0.36% | +145.28% | 20.88B | |
| +1.46% | +1.60% | +62.58% | +98.84% | 15.64B | |
| Average | +1.27% | +2.06% | +68.72% | +48.17% | 38.18B | |
| Weighted average by Cap. | +0.60% | +2.93% | +95.55% | +38.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.5M 6.53M 6.18M 5.62M 10.49M 718M 10.55M 73.64M 28.47M 365M 28.17M 27.55M 1.17B | 4.3M 3.75M 3.54M 3.22M 6.02M 412M 6.05M 42.22M 16.33M 209M 16.15M 15.79M 670M |
| Net income | -27.3M -23.78M -22.5M -20.45M -38.2M -2.61B -38.39M -268M -104M -1.33B -103M -100M -4.25B | -23.6M -20.56M -19.45M -17.68M -33.02M -2.26B -33.18M -232M -89.6M -1.15B -88.66M -86.68M -3.68B |
| Net Debt | - | - |
Employees
26
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/09/26 | $0.8500 | +4.94% | 79,724 |
| 16/09/26 | $0.8100 | +1.25% | 18,229 |
| 15/09/26 | $0.8000 | +1.91% | 15,816 |
| 14/09/26 | $0.7850 | -3.09% | 67,956 |
| 11/09/26 | $0.8100 | +1.22% | 25,017 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8500USD
Average target price
5.000USD
Spread / Average Target
+488.24%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ELUT Stock
Select your edition
All financial news and data tailored to specific country editions
